4-Amino-2-[2-(2-amino-5-methoxyphenyl)-2-oxoethyl]-4-oxobutanoic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-Amino-2-[2-(2-amino-5-methoxyphenyl)-2-oxoethyl]-4-oxobutanoic acid
• 英文别名: 4-amino-2-[2-(2-amino-5-methoxyphenyl)-2-oxoethyl]-4-oxobutanoic acid
• 化学式: C₁₃H₁₆N₂O₅
• 分子量: 280.28
• InChiKey: UIVVCHQXIVQSKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  133
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Maturation of mammalian hepatocytes
  申请人：Takara Bio Europe AB

  公开号：US10913932B2

  公开（公告）日：2021-02-09

  The present invention relates to directed differentiation and maturation of mammalian hepatocytes, such as human hepatocytes. The hepatocyte obtained in accordance with the present invention show a phenotype which is more similar to that of primary hepatocytes than previously shown. In particular, the present invention relates to exposure of mammalian hepatocytes, such as human hepatocytes, to at least one maturation factor selected from the group consisting of Src kinase inhibitors, vitamin D including precursors, metabolites and analogs thereof, hypoxia inducing compounds, sphingosine and sphingosine derivatives, activators of peroxisome proliferator-activated receptors (PPARs), platelet-activating factor (PAF), PKC inhibitors, and combinations thereof.

  本发明涉及哺乳动物肝细胞（如人类肝细胞）的定向分化和成熟。根据本发明获得的肝细胞显示的表型比以前显示的更类似于原代肝细胞的表型。特别是，本发明涉及将哺乳动物肝细胞（如人类肝细胞）暴露于至少一种成熟因子，该因子选自由 Src 激酶抑制剂、维生素 D（包括其前体、代谢物和类似物）、缺氧诱导化合物、鞘磷脂和鞘磷脂衍生物、过氧化物酶体增殖激活受体（PPAR）激活剂、血小板激活因子（PAF）、PKC 抑制剂及其组合组成的组。
• MATURATION OF MAMMALIAN HEPATOCYTES
  申请人：Takara Bio Europe AB

  公开号：EP3303566A2

  公开（公告）日：2018-04-11
• [EN] MATURATION OF MAMMALIAN HEPATOCYTES<br/>[FR] MATURATION D'HÉPATOCYTES DE MAMMIFÈRES
  申请人：TAKARA BIO EUROPE AB

  公开号：WO2016193441A2

  公开（公告）日：2016-12-08

  The present invention relates to directed differentiation and maturation of mammalian hepatocytes, such as human hepatocytes. The hepatocyte obtained in accordance with the present invention show a phenotype which is more similar to that of primary hepatocytes than previously shown. In particular, the present invention relates to exposure of mammalian hepatocytes, such as human hepatocytes, to at least one maturation factor selected from the group consisting of Src kinase inhibitors, vitamin D including precursors, metabolites and analogs thereof, hypoxia inducing compounds, sphingosine and sphingosine derivatives, activators of peroxisome proliferator-activated receptors (PPARs), platelet-activating factor (PAF), PKC inhibitors, and combinations thereof.